LIXT Lixte Biotechnology Holdings, Inc. featured news, full reports, and detailed charts
Lixte Biotechnology Holdings, Inc. (LIXT/LIXT.OB) Wrap Up:
Lixte Biotechnology Holdings, Inc. develops tests for the early detection of cancers in the United States. Its tests are used for the estimation of prognosis, monitoring of treatment response, and to reveal targets for development of treatments. The company focuses on the discovery of biomarkers for common cancers that would enable identification of the presence of cancer at a stage curable by surgery. It also engages in the development of new treatments for brain cancer of adults, glioblastoma multiforme. The company has a cooperative research and development agreement with National Institute of Neurological Disorders and Stroke of the National Institutes of Health to identify and evaluate ...www.lixte.com
Founded in 2005
Lixte Biotechnology Holdings, Inc. (LIXT:OTC Bulletin Board Market)
LAST $0.51 USD
CHANGE TODAY 0.00 0.00%
VOLUME 0.0
As of November 19, 2009 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Lixte Biotechnology Holdings, Inc. (LIXT)
|
OPEN
--
|
PREVIOUS CLOSE
$0.51
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
07/17/09 - $1.01
|
52 WEEK LOW
03/5/09 - $0.16
|
|
|
MARKET CAP
15.0M
|
AVERAGE VOLUME 3 mo
10.2K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
29.5M
|
|
|
LIXT Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
LIXT Top Compensated Officers
No compensation data is available at this time for the top officers at this company.
Executives, Board Directors
Key developments for Lixte Biotechnology Holdings, Inc. (LIXT)
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
07/2/2009
Lixte Biotechnology Holdings Inc. announced that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte. The report was published online in the early edition (June 29) of the Proceedings of the National Academy of Science (US). The print version will appear July 14.
Lixte Biotechnology Holdings Inc. Auditor Raises 'Going Concern' Doubt
03/31/2009
Lixte Biotechnology Holdings Inc. filed its 10-K on March 31, 2009 for the period ending December 31, 2008. In this report its auditor, Weinberg & Company, P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Lixte Biotechnology Holdings Inc. Announces Change of Accounting Firm
12/22/2008
Lixte Biotechnology Holdings Inc. announced that on December 17, 2008, AJ Robbins P.C. was dismissed as the independent accountant. The Board of Directors acting in the capacity of an audit committee approved the dismissal of Robbins. On December 17, 2008, the company's Board of Directors acting in the capacity of an audit committee engaged Weinberg & Company P.A. as the company's new independent accountant to act as the principal accountant to audit the company's financial statements.
LIXT Competitors
| Company | Last | Change | |
| No competitor information is available for LIXT. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | LIXT | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
LIXT |
||
LIXT transactions
| Type Date |
Target |
|
Private Placement
November 6, 2009 |
-- |
More Recent News About Lixte Biotechnology Holdings, Inc.
More news for LIXT
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report
Show all filings for LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Request a Trial to NEW EDGAR Online Pro Form 10-Q for LIXTE BIOTECHNOLOGY HOLDINGS, INC. 12-Nov-2009Quarterly Report Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purpo...Click here to read the whole Article (external link)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
Show all filings for LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for LIXTE BIOTECHNOLOGY HOLDINGS, INC. 6-Nov-2009Unregistered Sale of Equity Securities Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for...Click here to read the whole Article (external link)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statemen
Show all filings for LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for LIXTE BIOTECHNOLOGY HOLDINGS, INC. 12-Aug-2009Entry into a Material Definitive Agreement, Financial Statemen Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All i...Click here to read the whole Article (external link)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview On June 30, 2006, Lixte Biotechnology, Inc., a privately held Delaware corporation ("Lixte"), completed a reverse merger transaction with SRKP 7, Inc. ("SRKP"), a non-trading public shell company, whereby Lixte became a wholly owned subsidiary of SRKP. On December 7, 2006, SRKP amended its Certificate of Incorporation to change its name to Lixte Biotechnology Holdings, Inc. ("Holdings"). Unless the context indicates otherwise, Lixte and Holdings are hereinafter referred to as the "Company". For financial reporting purposes, Lixte was considered the accounting acquirer in the merger and the merger was accounted for as a reverse merger. Accordingly, the historical financial statements presented herein are those of Lixte and do not include the historical financial results of SRKP. The stockholders' equity section of SRKP has been retroactively restated for all periods presented to reflect the accounting effect of the reverse merger transaction. All costs associated with the reverse merger transaction were expensed as incurred. Lixte was incorporated in Delaware on August 9, 2005 to capitalize on opportunities to develop low cost, specific and sensitive tests for the early detection of cancers to better estimate prognosis, to monitor treatment response, and to reveal targets for development of more effective treatments. The Company is considered a "development stage company" as defined in Statement of Financial Accounting Standards ("SFAS") No. 7, "Accounting and Reporting by Development Stage Enterprises", as it has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and is dependent on debt and equity funding to finance its operations. The Company has selected December 31 as its fiscal year end. Going Concern The Company's ...Click here to read the whole Article (external link)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
Show all filings for LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for LIXTE BIOTECHNOLOGY HOLDINGS, INC. 24-Apr-2009Unregistered Sale of Equity Securities Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" f...Click here to read the whole Article (external link)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 10-K, Annual Report
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview On June 30, 2006, Lixte Biotechnology, Inc., a privately held Delaware corporation ("Lixte"), completed a reverse merger transaction with SRKP 7, Inc. ("SRKP"), a non-trading public shell company, whereby Lixte became a wholly owned subsidiary of SRKP. On December 7, 2006, SRKP amended its Certificate of Incorporation to change its name to Lixte Biotechnology Holdings, Inc. ("Holdings"). Unless the context indicates otherwise, Lixte and Holdings are hereinafter referred to as the "Company". For financial reporting purposes, Lixte was considered the accounting acquirer in the merger and the merger was accounted for as a reverse merger. Accordingly, the historical financial statements presented herein are those of Lixte and do not include the historical financial results of SRKP. The stockholders' equity section of SRKP has been retroactively restated for all periods presented to reflect the accounting effect of the reverse merger transaction. All costs associated with the reverse merger transaction were expensed as incurred. Lixte was incorporated in Delaware on August 9, 2005 to capitalize on opportunities to develop low cost, specific and sensitive tests for the early detection of cancers to better estimate prognosis, to monitor treatment response, and to reveal targets for development of more effective treatments. The Company is considered a "development stage company" as defined in Statement of Financial Accounting Standards ("SFAS") No. 7, "Accounting and Reporting by Development Stage Enterprises", as it has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and is dependent on debt and equity funding to finance its operations. The Company has selected December 31 as its fiscal year end. Going Concern The Com...Click here to read the whole Article (external link)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
Show all filings for LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for LIXTE BIOTECHNOLOGY HOLDINGS, INC. 3-Mar-2009Unregistered Sale of Equity Securities Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for...Click here to read the whole Article (external link)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
Show all filings for LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for LIXTE BIOTECHNOLOGY HOLDINGS, INC. 17-Feb-2009Unregistered Sale of Equity Securities Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" f...Click here to read the whole Article (external link)
Would you like to leave a comment about Lixte Biotechnology Holdings, Inc. LIXT/LIXT.OB
Find out what social network information about Lixte Biotechnology Holdings, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Lixte Biotechnology Holdings, Inc. there is more great information available at Realpennies.com